Skip to main content

Todos Medical's Letter of Intent with Provista Diagnostics set to license sepsis diagnostic testing

Todos Medical president and CEO Gerald Commissiong joins Proactive's Natalie Stoberman to discuss news of the company entering a Letter of Intent with Provista Diagnostics to license PCR-based sepsis diagnostic test AcuSept LDT rights From Acumen Diagnostics.

Todos Medical engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma.

Contact Details

Proactive Investors

+1 347-449-0879

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.